Right on the heels of our press release announcing a deal with Novo Nordisk, we're thrilled to see this NY Times coverage of the partnership and Variant Bio's ethics-first approach to drug discovery:

Variant Bio recently kicked off another new study with Novo Nordisk, this time in Samoa in partnership with Oceania University of Medicine:

Prof. Lyn Griffiths from Queensland University of Technology visited Norfolk Island to check in on benefit-sharing initiatives:

In our newest publication in @TrendsGenetics, we argue for the importance of tailoring research results according to cultural context and community input:

We recently joined the team from the Mochtar Riady Institute for Nanotechnology to share research results with communities in Java and Bali:

“We may have traveled in different boats, but we’re all on the same ship.” — Words of wisdom from @VariantBio’s collaborator Dr. Herawati Sudoyo at the Asia-Pacific Conference for Human Genetics in Yogyakarta, Indonesia last week, together with the amazing team from MRIN:

We joined research partners in Tahiti to kick off recruitment for an expansion of Variant Bio’s 2022 collaborative study with GHICL:

Caught @OliviaG_PhD's talk at #ASHG25 and interested in more of @VariantBio's work? Here's a recent publication from Variant in @HGGAdvances on body composition associations in a Malagasy cohort:

Stacey Drabic, Variant Bio’s SVP of Research, describes how she is building and advancing our translational research strategy:

Honored that Variant Bio has been named to @NorrskenVC’s Impact/100 list of the 100 most promising impact startups worldwide. This recognition underscores the importance of ethically grounded innovation. Thank you to Norrsken for the honor, and for the spotlight in Times Square!

Spotlight on the Ethnographic Praxis in Industry Conference (#EPIC2025) by Sarah LeBaron von Baeyer, Variant Bio’s Director of Ethics & Engagement:

Highlights of a talk presented by @kstsosie at @VariantBio in honor of International Day of the World's Indigenous Peoples:

This year, @VariantBio was delighted to be a sponsor of SING Australia's 2025 Summer Internship for Indigenous Peoples in Genomics: https://t.co/tpKYX1Xuvm. Congratulations to all participants, and to the team at SING for making genomics accessible for Indigenous Australians.

“They’re solving the biggest bottleneck that exists in drug discovery.” -- John Xue, SoftBank Investment Advisers (for more, read the recent Sōzō Insights feature piece highlighting Variant Bio's unique approach to drug discovery):

Explore our life sciences thesis by Alessandra, Ken, and Elena ↓

Since 2021, we’ve invested approximately $700M across more than 30 companies, partnering at every stage—from seed and company creation to public market entry—to seek to drive innovation in this space. Breakthroughs in biology are converging with advances in applied AI and

Our SABR manuscript is out in Nature Genetics. SABR is the largest functional genomics dataset from a continental African cohort. We mapped the genetic architecture of blood expression, splicing, and cell types in over 600 individuals from 3 SEB groups. https://t.co/zZKWM2Po1r

Variant Bio and @WitsUniversity unveil the largest functional genomics resource ever created for a continental African population out now in @NatureGenet:

Team members from @VariantBio visited Brisbane, Australia to present on genomics research and meet with study collaborators in Queensland:

Variant Bio visits long-term partners in the Faroe Islands to celebrate the end of participant recruitment and kick off data generation together:

We have distributed over $1 million USD in short-term benefits for genomic research projects spanning six continents: